Le Lézard
Classified in: Health, Business
Subject: BUSINESS CONTRACTS

Extendicare Announces Closing of Transactions with Revera


MARKHAM, Ontario, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Extendicare Inc. ("Extendicare") (TSX: EXE.TO) announced today that it has completed the previously announced transactions with Revera Inc. and its affiliates ("Revera") in respect of the ownership, operation and redevelopment of long-term care homes in Ontario and Manitoba. Highlights of the transactions include:

The Revera transactions, combined with the earlier sale of Extendicare's portfolio of retirement communities in 2022, advance Extendicare's strategy to focus on LTC and home health care using a less capital-intensive, higher margin business model. Extendicare will focus its growth on operating and building new LTC homes, expanding its Managed Services segment through the provision of management and consulting services, and growing its home health care business.

"Today marks another significant milestone in Extendicare's strategic re-positioning to focus on growth in our long-term care and home health care segments. We are thrilled to expand our highly trained workforce of health care professionals by welcoming Revera's long-term care team, bringing together two of the most experienced seniors' care teams in Canada. We look forward to leveraging our combined scale and expertise to drive improved performance and advance the delivery of high-quality care for Canadian seniors," said Dr. Michael Guerriere, President and CEO. "The challenge of replacing long-term care infrastructure that is past its useful life is a serious issue for the health sector. We are now even better positioned to be a driving force in the solution given our vibrant resident communities, strong care teams and integral role in building more and better homes. We are keen to work with Revera and Axium to replace Revera's older long-term care homes in Ontario as approvals and favourable market conditions permit, giving us the opportunity to acquire ownership either alone, or with Axium, as the new homes are redeveloped."

The aggregate cash consideration for the Revera transactions was approximately $32.6 million, net of holdbacks, plus the assumption of approximately $37.1 million in debt (Extendicare's share of JV debt), subject to customary post-closing adjustments. The purchase price was funded from cash on hand.

The previously announced transaction with Axium to form a joint venture to redevelop Extendicare's Class C LTC homes has received regulatory approval and is anticipated to close before the end of the third quarter, subject to customary closing conditions.

For further information on the transactions with Revera and Axium, please refer to the discussion in Extendicare's 2022 Annual Information Form under the section "General Development of the Business ? Acquisitions and Dispositions ? Revera and Axium Transactions" which is available on Sedar at www.sedar.com.

Advisors

BMO Capital Markets acted as financial advisor to Extendicare and Torys LLP acted as legal advisor to Extendicare in connection with these transactions. Stikeman Elliott LLP acted as legal advisor to Axium in connection with these transactions. Stormont Partners Advisory acted as financial advisor to Revera and Goodmans LLP acted as legal advisor to Revera in connection with the Revera transactions.

Forward-looking Statements

This press release contains forward-looking statements concerning anticipated future events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation, statements regarding the Revera and Axium transactions and the impact on our business from the Revera transactions. Forward-looking statements can often be identified by the expressions "anticipate", "believe", "estimate", "expect", "intend", "objective", "plan", "project", "will" or other similar expressions or the negative thereof. These forward-looking statements reflect Extendicare's current expectations regarding future results, performance or achievements and are based upon information currently available to us and on assumptions that Extendicare believes are reasonable. Extendicare assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied in the statements. For further information on the risks, uncertainties and assumptions that could cause Extendicare's actual results to differ from current expectations, refer to "Risk and Uncertainties" and "Forward Looking-Statements" in Extendicare's 2022 MD&A and Q1 2023 MD&A filed by Extendicare with the securities regulatory authorities, available at www.sedar.com and on Extendicare's website at www.extendicare.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare's forward-looking statements.

For further information, please contact:

Investor Inquiries:

David Bacon
Senior Vice President and Chief Financial Officer
Email: [email protected]
Phone: (905) 470-4000

Media Inquiries:

Laura Gallant
Senior Manager, External Relations
Email: [email protected]
Phone: (416) 895-5676

 



These press releases may also interest you

at 12:20
Aurinia Pharmaceuticals Inc. (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. Shareholders re-elected five of nine incumbent directors to the Board of...

at 12:05
The Police Benevolent Association of the City of New York (PBA) has been honored with the Kidneys for Communities National Community Impact Award in recognition of its dedication and commitment to promoting living kidney donation and supporting the...

at 12:01
INITIATION NOTE: BrainStorm Cell Therapeutics Inc.  is focused on developing autologous mesenchymal stem cell (MSC) therapies for the treatment of neurodegenerative diseases (NDDs) ? BCLI's primary...

at 12:01
The board of directors of Abbott today declared a quarterly common dividend of 55 cents per share. This marks the 402nd consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2024, to shareholders of...

at 12:00
Sleep Doctor, the leading online source for sleep health, improvement, and education, has published a recent survey report examining the relationship between sleep and work. The report also provides insights into the sleep disparities between men and...

at 12:00
Being physically active helps to improve our physical and mental health. Regular physical activity can also help to prevent chronic disease. That's why the Government of Canada is proud to invest in community-based initiatives that are providing more...



News published on and distributed by: